CD8A and neoplasm: Combining the presence of intratumoral CD8+ TILs and of PD-L1 on tumor cells, we distinguished between the following TMITs: type I—11/57 (19%); type II—31/57 (54%); and type III—15/57 (26%) (Table 1, Figure 1).